{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:53:28Z","timestamp":1778000008416,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,23]],"date-time":"2016-04-23T00:00:00Z","timestamp":1461369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10157-016-1266-8","type":"journal-article","created":{"date-parts":[[2016,4,23]],"date-time":"2016-04-23T12:21:19Z","timestamp":1461414079000},"page":"143-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children"],"prefix":"10.1007","volume":"21","author":[{"given":"Biswanath","family":"Basu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binu George","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. K. S.","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,23]]},"reference":[{"key":"1266_CR1","first-page":"CD002290","volume":"10","author":"N Pravitsitthikul","year":"2013","unstructured":"Pravitsitthikul N, Willis NS, Hodson EM, et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev. 2013;10:CD002290.","journal-title":"Cochrane Database Syst Rev"},{"key":"1266_CR2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","volume":"28","author":"RM Lombel","year":"2013","unstructured":"Lombel RM, Gipson DS, Hodson EM. Kidney disease: improving global outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013;28:415\u201326.","journal-title":"Pediatr Nephrol"},{"key":"1266_CR3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR inchildren with CKD. J Am Soc Nephrol. 2009;20:629\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"1266_CR4","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/0140-6736(91)93257-A","volume":"337","author":"British Association for Paediatric Nephrology","year":"1991","unstructured":"British Association for Paediatric Nephrology. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. Lancet. 1991;337:1555\u20137.","journal-title":"Lancet"},{"key":"1266_CR5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000187855","volume":"66","author":"U Dayal","year":"1994","unstructured":"Dayal U, Dayal AK, Shastry JC, et al. Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children. Nephron. 1994;66:408\u201312.","journal-title":"Nephron"},{"key":"1266_CR6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s00467-005-1943-4","volume":"20","author":"AF Donia","year":"2005","unstructured":"Donia AF, Ammar HM, El-AgroudyAel-B, et al. Long-term results of two unconventional agents in steroid-dependent nephrotic children. Pediatr Nephrol. 2005;20:1420\u20135.","journal-title":"Pediatr Nephrol"},{"key":"1266_CR7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00467-005-2080-9","volume":"21","author":"K Al Saran","year":"2006","unstructured":"Al Saran K, Mirza K, Al Ghanam G, et al. Experience with levamisole in frequently relapsing, steroid dependent nephrotic syndrome. Pediatr Nephrol. 2006;21:201\u20135.","journal-title":"Pediatr Nephrol"},{"key":"1266_CR8","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","volume":"23","author":"EM Dorresteijn","year":"2008","unstructured":"Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, et al. Mycophenolatemofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008;23:2013\u201320.","journal-title":"Pediatr Nephrol"},{"key":"1266_CR9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00467-011-2006-7","volume":"27","author":"V Baudouin","year":"2012","unstructured":"Baudouin V, Alberti C, Lapeyraque AL, et al. Mycophenolatemofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol. 2012;27:389\u201396.","journal-title":"Pediatr Nephrol"},{"key":"1266_CR10","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann J, Weber L, Pape L, Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie (GPN), et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24:1689\u201397.","journal-title":"J Am Soc Nephrol"},{"key":"1266_CR11","first-page":"1326","volume":"8","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transpl. 1993;8:1326\u201332.","journal-title":"Nephrol Dial Transpl"},{"key":"1266_CR12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/ki.2008.24","volume":"73","author":"K Ishikura","year":"2008","unstructured":"Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167\u201373.","journal-title":"Kidney Int"},{"key":"1266_CR13","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00467-012-2228-3","volume":"27","author":"W Wang","year":"2012","unstructured":"Wang W, Xia Y, Mao J, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol. 2012;27:2073\u20139.","journal-title":"Pediatr Nephrol"},{"key":"1266_CR14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/adc.48.4.286","volume":"48","author":"TM Barratt","year":"1973","unstructured":"Barratt TM, Cameron JS, Chantler C, et al. Comparative trial of 2\u00a0weeks and 8\u00a0weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Arch Dis Child. 1973;48:286\u201390.","journal-title":"Arch Dis Child"},{"key":"1266_CR15","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/adc.65.10.1147","volume":"65","author":"N Ueda","year":"1990","unstructured":"Ueda N, Kuno K, Ito S. Eight and 12\u00a0week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child. 1990;65:1147\u201350.","journal-title":"Arch Dis Child"},{"key":"1266_CR16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00467-003-1404-x","volume":"19","author":"N Prasad","year":"2004","unstructured":"Prasad N, Gulati S, Sharma RK, et al. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2004;19:494\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1266_CR17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1266_CR18","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"1266_CR19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850\u201363.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1266-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-016-1266-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1266-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1266-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:13:16Z","timestamp":1567815196000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-016-1266-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,23]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1007\/s10157-016-1266-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,23]]}}}